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Abstract
Background Children and adolescents with attention deficit hyperactivity disorder (ADHD) are at higher risk of all-cause 
poisoning by drugs and chemicals (intentional or accidental). Currently, there is limited data on whether medication treat-
ment for ADHD can reduce the risk of all-cause poisoning.
Methods Patients aged 5–18 years with a methylphenidate (MPH) prescription and an incident poisoning diagnosis between 
January 2001 and June 2020 were identified from the Hong Kong Clinical Data Analysis and Reporting System. A self-
controlled case series study design was used to compare the incidence rate ratios (IRRs) of all-cause poisoning during dif-
ferent risk windows (30 days before the first MPH prescription, exposure periods within 30 days of the first prescription, and 
periods of subsequent exposure) compared with the reference window (other non-exposure periods).
Results 42,203 patients were prescribed ADHD medication in Hong Kong during the study period. Of these, 417 patients 
who had both an MPH prescription and poisoning incident recorded were included in the main analysis. Compared with 
other non-exposed periods, a higher risk of poisoning was found in the 30 days before the first prescription (IRR 2.64, 
95% confidence interval [CI] 1.33–5.22) and exposure periods within 30 days of the first prescription (IRR 2.18, 95% CI 
1.06–4.48), but not during prolonged exposure. However, compared with 30 days before the first prescription as well as 
exposure periods within 30 days of the first prescription, there was a lower risk during the subsequent exposure (IRRs 0.49 
and 0.60, respectively). Similar results to the main analysis were also found in the subgroup analysis of intentional poisoning 
and females, but not in that of accidental poisoning and males.
Conclusions The risk of all-cause poisoning was higher shortly before and after the first MPH prescription and became 
lower during the subsequent prescription period. Our results do not support an association between the use of MPH and an 
increased risk of all-cause poisoning in children and adolescents and, in fact, suggest that longer-term use of MPH may be 
associated with a lower risk of all-cause poisoning, although this latter finding requires further study.
Le Gao and Kenneth K. C. Man have contributed equally as co-
first authors
 * Ian C. K. Wong 
 wongick@hku.hk
Extended author information available on the last page of the article
1 Introduction
Attention deficit hyperactivity disorder (ADHD) is a common 
neurodevelopmental disorder in children and adolescents [1, 2]. 
It is estimated that around 5% to 7% of children and adolescents 
worldwide [3] and 6.4% in Hong Kong (HK) [4] are affected 
by ADHD. ADHD is frequently associated with various psy-
chiatric comorbidities, including oppositional defiant disorder, 
anxiety, depression, substance misuse, and bipolar disorder [2, 
5]. The core ADHD symptoms include inattention, hyperac-
tivity and/or impulsivity [2, 6], and both core symptoms and 
comorbidities contribute to higher risks of injury [7–9], suicide 
[10, 11], and all-cause poisoning by drugs and chemicals (inten-
tional or accidental) [12]. Some of these risks such as injury and 
accident have been proven to reach a particularly high level in 
youth (12–25 years) [13], which could be explained by the fact 
that the core symptoms may be more pronounced in children 
and adolescents [14], or that research on ADHD and accidents/
injuries have focused more on a specific age group (in young 
people) [13]. Poisonings due to medication and chemicals are 
very common in children and adolescents, with an estimated 
45,000 deaths due to this cause worldwide every year [15]. 
Results from a cohort study showed that children and young 
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Key Points 
Current studies have explored the risk of all-cause 
poisoning in patients with attention deficit hyperactiv-
ity disorder (ADHD) versus those without ADHD, or 
reported poisoning cases from ADHD medication to 
poison centres. However, no population-based study has 
investigated whether medication treatment for ADHD 
can reduce the risk of all-cause poisoning.
This study showed that the risk of all-cause poison-
ing was higher shortly before and after the initiation of 
methylphenidate, followed by a decreased risk during the 
subsequent long-term methylphenidate treatment.
Along with previous ecological studies, safe storage 
and management of ADHD medication should still be 
emphasised to both patients and family members.
managed by the HK Hospital Authority (HA) that includes 
healthcare records since 1995 from all public hospitals 
and clinics in HK. It includes data from these health care 
facilities that are available to all HK residents (>7.3 mil-
lion) and covers approximately 80% of all hospital admis-
sions in HK [21]; moreover, the majority of children who 
have chronic conditions are under the care of the HK HA 
[22]. The database includes inpatient, outpatient (ambula-
tory care), and accident and emergency (A&E) department 
admission records. Information including diagnosis, hospi-
tal admissions and discharges, prescription and dispensing 
information is recorded and well protected by using de-
identified patient ID. Data from CDARS has been validated 
and utilised for pharmacoepidemiological research [23–27]. 
The study protocol was approved by the Institutional Review 
Board of the University of Hong Kong/ Hospital Authority 
Hong Kong West Cluster (Reference No. UW 12-136).
2.2  Study Design
We used a self-controlled case series (SCCS) design to com-
pare the incidence of the outcome of interest (poisoning), 
during the exposure (MPH treatment) period, with that in the 
non-exposure (non-treatment) period [28]. In SCCS studies, 
only patients who experienced both exposure and outcome 
are included. This within-individual comparison approach 
has several advantages as it controls for time-invariant con-
founders, both measured and unmeasured, that vary between 
individuals (i.e. genetic factors, disease severity, underly-
ing comorbidities and socioeconomic status), and eliminates 
selection biases related to control groups that are common in 
cohort and case-control study designs that rely on between-
individual comparison [29, 30].
2.3  Patients Selection
We selected children and adolescents aged 5–18 years who 
received at least one prescription of MPH and experienced 
incident poisoning during the period 1 January 2001 to 30 
June 2020 from a cohort of individuals with ADHD medi-
cation prescriptions. Individual observation periods com-
menced at the study start date (1 January 2001), the first day 
of clinical record in CDARS, or 5th birthday, whichever was 
latest, and ended at the study end date (30 June 2020), one 
day before 19th birthday, prescription date of atomoxetine or 
the registered date of death, whichever was earliest. Patients 
with prescription(s) for atomoxetine were censored at their 
first atomoxetine prescription to avoid co-prescribing situ-
ations that may affect comparisons. MPH and atomoxetine 
were the only ADHD medications available in HK during 
the study period, and over 90% of patients were on MPH 
[31]. Therefore, this study has accounted for the majority of 
ADHD medication users in HK. We set the lower limit for 
people with ADHD are at a four-fold higher risk of poisoning 
compared with those without ADHD [7]. Similar results were 
also reported in a recent meta-analysis, with a pooled relative 
risk of 3.14 from nine studies [12]. Notably, authors of the 
meta-analysis highlighted the need for further research focus-
ing on the impact of medication treatment for ADHD on the 
risk of all-cause poisoning [12].
Stimulants such as methylphenidate (MPH) and ampheta-
mines, and non-stimulants like atomoxetine, are common 
treatments for ADHD [16]. Over the past two decades, ADHD 
medication use has increased in many countries and regions, 
such as the United States (US), the United Kingdom, Australia 
and HK [17]. Ecological (analysis of secular trends) stud-
ies in the US [18] and Australia [19] observed an increasing 
trend of poisoning cases from ADHD medication reported to 
poison centres. However, it has remained unclear whether the 
increased use of pharmacological treatment of ADHD has a 
protective effect on the risk of overall poisoning.
Theoretically, ADHD medications could reduce the risk 
of poisoning in patients with ADHD by controlling core 
symptoms [20]. Hence, Ruiz-Goikoetxea et al. hypothesised 
that patients receiving ADHD medications are at a lower 
risk of all-cause poisoning [12]. Our study aims to test this 
hypothesis by comparing the risk of all-cause poisoning 
between MPH treatment and non-treatment periods.
2  Methods and Materials
2.1  Database
We obtained data through the Clinical Data Analysis 
and Reporting System (CDARS), an electronic database 
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follow-up at 5 years of age, as MPH is not recommended for 
younger children [16].
2.4  Exposure
The exposure window was defined as the periods of MPH 
use documented in the prescription records. If the prescrip-
tion duration was not available, the prescribed quantity, fre-
quency and strength were used to calculate the exposure 
window. Median imputation was applied for the missing 
duration of a very small proportion (0.07%). We did not 
assume that patients received continuous treatment upon 
MPH initiation because clinicians may offer drug holidays 
to ADHD patients during school holidays [23, 25, 32]. Three 
cut-off points were used to define the individual study peri-
ods. Three risk windows (30 days before MPH was first 
prescribed, exposure periods within 30 days of the first 
prescription, and periods of subsequent exposure) and one 
reference window (other non-exposure periods) are defined 
in Fig. 1.
2.5  Outcome
The incident event was identified as the first poisoning event 
(all-cause, by drugs and chemicals, intentional or accidental) 
from the A&E admission record, or the diagnosis records 
(including records from inpatient, outpatient, and A&E) with 
the International Classification of Diseases, Ninth Revision, 
Clinical Modification (ICD-9-CM) code (E950-E952, inten-
tional poisoning; E850-E869, 960-989, accidental poison-
ing). To ensure that the occurrences of poisoning events 
were independent of each other, only the first poisoning 
event was included in the main analysis. The date of the 
poisoning event was defined as the attendance/admission 
date of the hospital episode.
2.6  Statistical Analysis
Firstly, we did a descriptive analysis of the ADHD medica-
tion cohort from 2000 to 2020 by plotting the trend of the 
cumulative patient number with ADHD medication treat-
ment as well as the number of poisoning episodes between 
5 and 18 years old every 6 months. In SCCS analysis, inci-
dence rate ratios (IRRs) and 95% confidence intervals (CIs) 
were estimated by comparing the incidence rate of poisoning 
events during different risk windows and other non-exposure 
periods using conditional Poisson regression. We controlled 
for age at the 1-year age band and seasonal effect (cut-off 
points: 1 March, 1 May, 1 September, 1 November) in the 
analysis and used a 5% significant level in all statistical anal-
yses. The spline-based SCCS model was used to describe 
the exposure effect.
Using 0.25 as the ratio of the risk period to the whole 
study period, 339 poisoning cases will be required to detect 
an IRR of 1.4 with 80% power and 5% significance level 
[33].
We also performed additional analyses to explore and 
validate our results. The diagnosis of otitis media was used 
as the negative control outcome for validation purposes. 
Currently, there is no evidence of a relationship between 
MPH and otitis media. If significant results are found, then 
unmeasured confounders might have been present and any 
significant findings in the main analysis would be ques-
tionable [34]. Subgroup analysis was conducted by sex 
and poisoning type (intentional poisoning and accidental 
poisoning). Sensitivity analyses included (i) extending the 
exposure periods by adding 1–10 weeks after the end of each 
prescription period to assess the effect of non-adherence; 
(ii) adding a 7-day washout period after each exposure to 
ensure the effect of ADHD medication does not distort the 
baseline risk of poisoning (Online Resource Fig. S1, see 
electronic supplementary material [ESM]); (iii) including 
patients with both MPH prescription and ADHD diagnosis 
(the commencement of individual observation periods was 
revised at the start of the study period, first diagnosis date of 
ADHD, or on the patient’s 5th birthday, whichever was lat-
est); (iv) using the first prescription date of antidepressants 
or antipsychotics during the study period as the censor date 
to lessen the impact of these drugs on the poisoning outcome 
(detailed names of these drugs are shown in Online Resource 
Table S1, see ESM); (v) including all poisoning episodes 
of individuals who were in the main analysis and calculat-
ing the incidence of poisoning episodes during the study 
period—poisoning cases happening within 2 days were 
regarded as one poisoning episode; and (vi) re-setting the 
first medication use if a patient experienced a period with-
out prescription longer than half a year or one year (Online 
Resource Fig. S2, see ESM).
Microsoft  Excel®, R v3.6.1, and Statistical Analysis 
 System® (SAS) v9.4 (SAS Institute Inc., Cary, NC, USA) 
were used for data analysis. LG and KM conducted the 
analysis independently for quality control.
3  Results
We identified 42,203 individuals with ADHD medication 
prescriptions from CDARS, of which 38,968 had at least one 
prescription between the ages of 5 and 18 years old. During 
the past 20 years, the number of ADHD medication users aged 
5–18 years and the number of poisoning episodes among this 
group of MPH users were increasing (Online Resource Fig. 
S3, see ESM). A total of 417 patients aged 5–18 years with 
an incident poisoning event and MPH prescription during the 
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study period were included in the main analysis, and a total of 
537 poisoning episodes identified in this group of individuals 
were included in the sensitivity analysis. The inclusion and 
exclusion steps of SCCS are shown in Fig. 2.
Baseline characteristics at the beginning of the obser-
vation period are listed in Table 1. The mean age at the 
study start date was 6.06 years, while the mean age at first 
MPH use was 10.11 years and 106 (25.4%) were female. The 
median duration of each prescription was 112 days, and the 
median duration of treatment was 1.89 years. There were no 
deaths recorded during the study period. Of the 417 patients, 
318 (76.3%) were diagnosed with ADHD, and 213 (51.1%) 
had at least one record of other psychiatric disorders before 
or during the study period (Online Resource Table S2, see 
ESM). The overall incidence of poisoning episodes was 
13.22 per 100 person-years during the study period (14.87 
per 100 person-years in the MPH exposure period and 12.62 
per 100 person-years in the non-exposure period).
3.1  Main Self‑Controlled Case Series (SCCS) Analysis
Following adjustments for age and seasonal effect, a higher 
risk of all-cause poisoning was observed during the 30 days 
before the first MPH prescription compared with other non-
exposure periods, with an IRR of 2.64 (95% CI 1.33–5.22). 
Compared with other non-exposure periods, the risk of 
all-cause poisoning remained elevated during exposure 
periods within 30 days of the first prescription (IRR 2.18, 
95% CI 1.06–4.48) (Table 2). However, during the period 
of subsequent exposure, there was no statistically signifi-
cant increase in risk compared with other non-exposure 
periods (IRR 1.30, 95% CI 0.99–1.71). Comparison with 
the 30 days before the first prescription (Online Resource 
Table S3, see ESM) showed that there was no increase in 
risk during exposure periods within 30 days of the first 
prescription (IRR 0.83, 95% CI 0.32–2.15). Furthermore, 
the risk of all-cause poisoning during the period of sub-
sequent exposure was lower compared with that observed 
in the 30 days before the first prescription (IRR 0.49, 95% 
CI 0.24–1.00), and was, although not statistically signifi-
cant, lower than exposure periods within 30 days of the 
first prescription (IRR 0.60, 95% CI 0.29–1.24). The spline-
based figure showed that the risk of all-cause poisoning 
kept increasing before the first use of MPH and reached a 
peak at around 50 days before the first prescription (Online 
Resource Fig. S4, see ESM).
Fig. 1  Illustration of main self-
controlled case series (SCCS) 
analysis. MPH methylphenidate, 
Rx prescription
30 days before 1st Rx Other non-exposure period(s)
Exposure period(s) within 30 days of 1st Rx
Subsequent exposure period(s)
Events of poisoning
1st MPH Rx 30th day after 1st Rx
Start End
Patient A
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Fig. 2  Patient inclusion flow-
chart. ADHD attention deficit 
hyperactivity disorder, MPH 
methylphenidate, SCCS self-
controlled case series
Patients of all ages with ADHD medication 
from 2001-2020 (N=42,203)
Patients with ADHD medication
and poisoning diagnosis (1,004 




Patients with MPH prescription 
and poisoning diagnosis (972 
individuals with 1,344 episodes)
Exclude: 1st ADHD 
medication of 
atomoxetine (N=32)
Exclude: Exposure or 







Included in the final SCCS 
analysis (417 individuals with 
537 episodes)
Patients with ADHD 
medication between 5 to 
18 years old (N=38,968)
Exclude: Out of 5 to 
18 years old (N=3,235)
Table 1  Patients’ characteristics in main SCCS analysis
IQR interquartile range, MPH methylphenidate, SCCS self-controlled case series, SD standard deviation
Characteristics Female Male Total
No. of patients (%) 106 (25.42) 311 (74.58) 417 (100)
Mean age [y] at baseline (±SD) 6.45 (2.70) 5.95 (1.84) 6.06 (2.06)
Mean age [y] of first prescription (±SD) 11.32 (3.27) 9.69 (2.76) 10.11 (2.98)
Mean age [y] at poisoning event (±SD) 12.41 (3.63) 11.35 (4.09) 11.62 (4.00)
Median days of each prescription (IQR) 112 (56–199) 112 (70–223.5) 112 (68–211)
Median years of MPH exposure (IQR) 1.00 (0.25–3.14) 2.12 (0.73–4.18) 1.89 (0.48–3.89)
Exposed period
 No. of incident poisoning cases 31 97 128
 No. of all poisoning episodes 47 112 159
 Follow-up time (person-years) 207.05 862.10 1069.15
Non-exposed period
 No. of incident poisoning cases 75 214 289
 No. of all poisoning episodes 128 250 378
 Follow-up time (person-years) 784.97 2209.43 2994.40
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3.2  Additional Analyses
The negative control analysis showed no association between 
MPH and otitis media, supporting the validity of our pri-
mary results (Online Resource Table S4, see ESM).
Subgroup analysis results are described in Table 3. For 
intentional poisoning, the risk was higher in 30 days before 
the first prescription and exposure periods within 30 days of 
the first prescription compared with the other non-exposure 
period, and decreased in the period of subsequent exposure 
compared with the period shortly before and after the first 
prescription (Online Resources Table S3, see ESM). For 
accidental poisoning, no significantly higher risk in the 30 
days before the first prescription and exposure periods within 
30 days of the first prescription compared with the other 
non-exposure periods was found. In the subgroup analysis 
by sex, the result for females was consistent with the main 
analysis. However, for males, there were no significant dif-
ferences between any of the three risk windows when com-
pared with other non-exposure periods with IRRs of 1.61, 
1.47, and 1.24, respectively. No interaction between sex and 
exposure was observed (p-value for interaction = 0.17).
The robustness of the main analysis was supported by 
the sensitivity analyses. IRRs were stable after adding 1–10 
weeks to each exposure period and also the 7-day wash-
out period (Online Resource Fig. S5 and Online Resource 
Table S5, see ESM). When we restricted the analysis to 
those with ADHD diagnosis, a higher risk was detected in 
exposure periods within 30 days of the first prescription; 
however, due to the limited sample size, no cases occurred 
in the 30 days before the first MPH prescription. Similar 
results were found when the prescription start date of anti-
depressant or antipsychotics was used as the censor date, 
including all poisoning episodes in the SCCS analysis as 
well as redefining a new start of MPH use (Online Resource 
Table S3 and Online Resource Table S5, see ESM).
4  Discussion
Despite a higher risk of all-cause poisoning in MPH users 
during 30 days before the first MPH prescription as well as 
exposure periods within 30 days of the first prescription, 
comparisons between other risk windows showed the risk 
was lowered in the period of subsequent exposure. These 
results do not support the notion that MPH use is associated 
with increased risk of intentional or accidental poisoning. 
The robustness of these results was supported by the sensi-
tivity and negative control analyses.
Biologically, it is not possible for MPH to exert any effect 
prior to the commencement of the MPH treatment. One 
possible reason for the observed increase in risk during the 
period shortly before starting medication could be related 
to the core ADHD symptoms or the related comorbidities. 
The core symptoms and those psychiatric comorbidities can 
increase the risk of behavioural and cognitive problems, 
hence the poisoning. While the reasons for increased risk 
in exposure periods within 30 days of the first prescription 
may be similar to that of 30 days before the first prescrip-
tion, it may also be the case that the higher risk during the 
initial prescribing period is related to the suboptimal treat-
ment of ADHD symptoms during the titration of MPH. It is 
also possible that in some cases, a poisoning event triggered 
the referral for assessment and subsequent identification of 
underlying ADHD prompted the commencement of MPH. 
In contrast, with the selected negative control event in this 
study, we did not identify the same risk pattern. These find-
ings lend support to the validity of the selection of our meth-
ods using SCCS analysis for this important public health 
issue.
We did not observe an immediate decrease in the risk of 
all-cause poisoning after MPH treatment initiation; however, 
the risk of all-cause poisoning in the subsequent prescription 
period was lower than in the two extra high-risk periods (i.e. 
30 days before and after initiation of MPH). The findings are 
indeed consistent with Ruiz-Goikoetxea et al.’s hypothesis 
that MPH reduces the core ADHD symptoms, which may in 
turn reduce the risk of all-cause poisoning [12]. Similarly, 
the use of ADHD medication and its association with lower 
risk of unintentional [35] and physical injury [36] have also 
been suggested in previous studies. However, it is important 
to consider that the association is not necessarily causal. 
Further research is needed to validate our findings and evalu-
ate the potential reasons for our observations.
Analysis of intentional poisoning showed a significantly 
higher risk in 30 days before the first prescription as well 
Table 2  Results of main SCCS analysis of the incident poisoning episode (N = 417)
CIs confidence intervals, IRRs incidence rate ratios, MPH methylphenidate, NA not applicable, Rx prescription, SCCS self-controlled case series
Risk window No. of events (follow-up person-years) Adjusted IRRs (95% CIs) p-value
Other non-exposure period(s) 280 (2962.86) 1.00 NA
30 days before first MPH Rx 9 (31.54) 2.64 (1.33–5.22) 0.005
Exposure period(s) within 30 days of first MPH Rx 8 (32.97) 2.18 (1.06–4.48) 0.03
Period(s) of subsequent exposure 120 (1036.18) 1.30 (0.99–1.71) 0.06
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as exposure periods within 30 days of the first prescription 
compared with other non-exposure periods with wide CIs, 
which is due to the limited number of cases that occurred 
within these risk windows. It also showed a lower risk in 
the period of subsequent exposure compared with those 
two high-risk windows. The intentional poisoning cases 
were partly reported in our previous analysis on self-harm 
[25], which suggests a higher risk in the 90 days before and 
after the first MPH prescription. For accidental poisoning, 
the direction of the estimates is consistent with the main 
analysis. Again, such results do not support an association 
between accidental poisoning and MPH prescription.
In the subgroup analysis by sex, results in females were 
similar to the main analysis and, despite a larger sample size, 
no significant results were found in males. This suggests that 
the risk of poisoning is likely to be higher in girls. According 
to the public data, the reported incidence of poisoning (all 
causes) in females aged between 5 and 18 years is higher 
than for males in that age group (0.07% vs 0.04%) [37, 38]. 
Additionally, sex differences in ADHD symptom severity 
may differ. For a variety of reasons, girls are less likely to 
be diagnosed with ADHD, and girls treated with MPH may 
have more severe symptoms [39, 40]. Unfortunately, we were 
not able to test this hypothesis due to the limitations of the 
dataset. However, according to the descriptive analysis in our 
study, more females (62.3%) than males (47.3%) had psychi-
atric comorbidities [41], which may explain the results.
Only 76% of the individuals of whom stimulants were 
prescribed had an ADHD diagnosis, which could be due to 
under-recording, or the need for MPH to control hyperac-
tivity symptoms in subjects with autism spectrum disorder 
(ASD). However, our primary aim is to investigate if there 
is an association between the use of MPH and the risk of 
all-cause poisoning regardless of the indication of the medi-
cation. Also, we utilised a within-individual method so the 
baseline chronic conditions will not affect our study esti-
mates. Therefore, our study conclusions were not affected 
by whether the included individuals had an ADHD diagnosis 
or not.
The main strength of our study is the use of the SCCS 
method, which relies on within-person comparison to bal-
ance fixed confounders as well as variable confounders of 
age and seasonal effect. Secondly, current research on the 
association between ADHD patients on medications and 
poisoning is limited, and so far, all studies are based on 
ecological data.
There are several limitations in this study. Firstly, we 
partly used the ICD-9-CM code to identify all-cause poi-
soning cases and classify the subtypes. Using ICD-9-CM 
may potentially affect the results by miscoding or misclas-
sification, whereas there is no evidence that such miscod-
ing will be affected by the MPH exposure. In such circum-
stances, it will reduce the sample size, hence the statistical 
power. Therefore, we identified the poisoning cases using 
Table 3  Results of subgroup analysis
CIs confidence intervals, IRRs incidence rate ratios, MPH methylphenidate, NA not applicable, Rx prescription
Factor Risk window No. of events 
(follow-up person-
years)
Adjusted IRRs (95% CIs) p-value
Analysis by poisoning type
 Intentional poisoning (N = 113) Other non-exposure period(s) 69 (848.67) 1.00 NA
30 days before first MPH Rx 4 (8.15) 5.64 (1.89–16.85) 0.001
Exposure period(s) within 30 days of first MPH Rx 3 (8.68) 4.16 (1.23–14.07) 0.02
Period(s) of subsequent exposure 37 (305.67) 1.15 (0.67–1.98) 0.61
 Accidental poisoning (N = 273) Other non-exposure period(s) 188 (1899.55) 1.00 NA
30 days before first MPH Rx 5 (21.01) 2.05 (0.83–5.05) 0.11
Exposure period(s) within 30 days of first MPH Rx 5 (21.80) 1.95 (0.79–4.80) 0.15
Period(s) of subsequent exposure 75 (662.44) 1.30 (0.92–1.84) 0.14
Analysis by sex
 Female (N = 106) Other non-exposure period(s) 70 (776.89) 1.00 NA
30 days before first MPH Rx 5 (8.08) 5.58 (2.13–14.62) <0.001
Exposure period(s) within 30 days of first MPH Rx 4 (8.11) 4.38 (1.54–12.46) 0.006
Period(s) of subsequent exposure 27 (198.94) 1.61 (0.90–2.88) 0.11
 Male (N = 311) Other non-exposure period(s) 210 (2185.97) 1.00 NA
30 days before first MPH Rx 4 (23.46) 1.61 (0.59–4.37) 0.35
Exposure period(s) within 30 days of first MPH Rx 4 (24.86) 1.47 (0.54–4.00) 0.45
Period(s) of subsequent exposure 93 (837.24) 1.24 (0.90–1.70) 0.19
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two methods to ensure that as many poisoning cases as 
possible can be identified; one method was the ICD-9-CM 
code, the other was the A&E admission record (extracted 
poisoning records of any poison type and poison nature). 
For the poisoning classification, although there are some 
diagnostic details in free text about the reason for poison-
ing, information was limited due to patient confidentiality; 
therefore, details of the specific chemicals or gas used for 
poisoning were not available. It is also likely that there were 
inconsistencies in the classification of whether a poisoning 
event was intentional or accidental. However, this study aims 
to examine the risk of poisoning regardless of the substance. 
Therefore, such limitations will not affect the conclusion 
of this study. Another limitation is the small sample size in 
some subgroups, so these analyses lacked statistical power. 
Further research using individual data from other popula-
tions is needed to confirm our findings and also evaluate the 
outcomes of other stimulant and also non-stimulant ADHD 
medications.
Our study does not support the hypothesis that the use of 
MPH in children and adolescents increases the risk of all-
cause poisoning; indeed, a lower risk was found in the period 
of subsequent treatment. This may provide some additional 
information for future guidelines, as prevention of poison-
ing has not been included in clinical practice guidelines as 
a benefit of ADHD pharmacotherapy. However, previous 
studies suggest that increased prescribing of ADHD medica-
tion is associated with an increased number of ADHD medi-
cation poisoning cases. Bringing all the current evidence 
together, a logical explanation to the increased poisoning 
cases with ADHD medication is that it could be related to 
poor storage and handling of such drugs. Epidemiological 
research has also shown that parents and siblings of children 
with ADHD are also more likely to have ADHD [42, 43] and 
this may increase the likelihood of poor storage and handling 
of MPH in the household. Therefore, in families with ADHD 
patients, family members with and without ADHD pharma-
cological treatment may face the risk of accidental poisoning 
due to ADHD medication. However, as there is currently a 
lack of detailed analysis of cases reported in different coun-
tries, we are unable to confirm our speculation. Therefore, 
further research on this topic is urgently needed to develop 
public health strategies to reverse the increasing occur-
rence of ADHD medication poisoning. In the meantime, we 
would like to emphasise educating carers and patients on the 
importance of safe handling and storage of MPH.
5  Conclusion
Children and adolescents prescribed MPH had a higher 
risk of all-cause poisoning shortly before and after the first 
prescription and the risk was reduced in the subsequent 
medication period. Our results do not support an associa-
tion between the use of MPH and an increased risk of all-
cause poisoning in children and adolescents and, in fact, 
suggest that longer-term use of MPH may be associated with 
a lower risk of all-cause poisoning, although this latter find-
ing requires further study.
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